New combo therapy for breast cancer aims to improve treatment without extra harm
NCT ID NCT07446686
First seen Mar 10, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This early-stage study tests whether adding a targeted drug (CDK4/6 inhibitor) to standard radiation therapy is safe and tolerable for women with a common type of high-risk breast cancer (HR+/HER2-). About 30 participants will receive the combination after surgery. Researchers will monitor side effects and use questionnaires to track how patients feel physically and emotionally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.